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Abstract
Staphylococcus aureus (SA) is a leading cause of a diverse spectrum of bacterial diseases, including abscesses. Nitric oxide
(NO) is a critical component of the natural host defense against pathogens such as SA, but its therapeutic applications have
been limited by a lack of effective delivery options. We tested the efficacy of a NO-releasing nanoparticle system (NO-np) in
methicillin-resistant SA (MRSA) abscesses in mice. The results show that the NO-np exert antimicrobial activity against MRSA
in vitro and in abscesses. Topical or intradermal NO-np treatment of abscesses reduces the involved area and bacterial load
while improving skin architecture. Notably, we evaluated pro- and anti-inflammatory cytokines that are involved in
immunomodulation and wound healing, revealing that NO-np lead to a reduction in angiogenesis preventing bacterial
dissemination from abscesses. These data suggest that NO-np may be useful therapeutics for microbial abscesses.
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Introduction
Staphylococcus aureus (SA) is an immotile Gram positive coccus that
frequently colonizes human nasal membranes and skin. This
bacterium is responsible for the majority of superficial and invasive
skin infections, resulting in over 12,000,000 outpatient/emergency
room visits [1] and 400,000 hospital admissions annually in the
USA [2]. Notably, in a study performed across multiple emergency
departments across the USA, MRSA was isolated from 61% of
abscesses and 53% of purulent wounds [3]. Furthermore, certain SA
clinical strains have recently evolved resistance to vancomycin, an
antibiotic to which staphylococci have previously been uniformly
sensitive. Although the vancomycin-resistant strains remain rare,
methicillin-resistant strains (MRSA) are increasingly common [4],
highlighting the urgent need to develop new approaches for the
treatment of SA infections. Furthermore, the incidence of com-
munity acquired strains of MRSA has markedly increased over the
past several years [5].
Topically applied nitric oxide (NO) is a potentially useful
preventive and therapeutic strategy against superficial skin
infections, including MRSA infections [6,7]. In the healthy state
and under pathologic conditions, it is well established that NO
maintains skin homeostasis by regulating circulation, ultraviolet-
mediated melanogenesis, sunburn erythema, and the maintenance
of the protective barrier against microorganisms [8]. Notably, NO
modulates immune responses [9] and is a significant regulator of
wound healing [10]. We have recently developed an inexpensive
and stable NO releasing platform using nanotechnology based on
a silane hydrogel [7]. Moreover, our platform benefits from the
presence of chitosan, which also has antimicrobial activity [11,12].
Chitosan is a polymer derived from crustacean exoskeletons that
binds to and disrupts the cell wall and membrane of microorgan-
isms due to its cationic charge in weakly acidic environments.
In this study, we investigate the applicability of topically applied
NO via nanoparticles (NO-np) to MRSA subcutaneous abscesses.
Based on our previous work [7,13] and the fact that NO can
penetrate skin, we hypothesized that NO-np can be microbicidal
to bacteria in an in vivo setting. To validate this hypothesis, we
investigated the biological impact of NO-np on MRSA using a
mouse infection model.
Results
NO-np Inhibits MRSA Growth
The effect of NO-np on MRSA growth was determined in real-
time for 24 h using Bioscreen C analysis (Fig. 1). NO-np
significantly reduced bacterial growth after 16 h co-incubation
when compared with MRSA grown with 1.25 (NO released from
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7804nps corresponding to 18.75 nM for the initial peak; 12.5 nM for
steady state) and 2.5 (37.5 nM for the initial peak; 25 nM for
steady state) mg/mL of np or medium alone. Interestingly, MRSA
grown with 5 (75 nM for the initial peak; 50 nM for steady state)
mg/mL np resulted in a significant reduction in bacterial growth
after 16 h, which is likely due to the effects of chitosan on the np.
However, after this time point the bacteria subjected to 5 mg/mL
np increased their replication rate.
Intradermal and Topical Administrations of NO-np
Decreased MRSA Burden in Subcutaneous Abscesses
To maximize the exposure of the NO-np to the bacteria in the
abscesses, we initially tested the compound by intradermally
administering NO-np into the MRSA abscesses. MRSA-infected
NO-np treated abscesses showed significantly lower microbial
burden than untreated or np-treated abscesses (P,0.001) (Fig. 2A).
To determine whether NO-np was similarly therapeutic via topical
application, mouse abscesses were topically-treated with NO-np.
Similar to the intra-abscess injection of NO-np, topical treatment
with NO-np significantly lowered microbial burden (CFU (log10)
4.8560.29) in comparison to untreated (CFU (log10) 5.5960.45)
(P,0.01) or np-treated abscesses (CFU (log10) 5.5060.24)
(P,0.001).
Histological examinations of MRSA-infected abscesses, both
untreated and np-treated, displayed a dense, neutrophil rich
infiltrate along with extensive cell necrosis (Fig. 2B). Tissue Gram
stains of these samples revealed large numbers of Gram positive
cocci (Fig. 2B; insets). Tissue sections from abscesses of NO-np
treated MRSA-infected mice revealed less suppurative inflamma-
tion along with increased fibrin deposition and a lower number of
bacteria (Fig. 2B; insets). Consistent with our prior work [13], NO-
np or np did not show toxicity on uninfected animals (data not
shown).
NO-np Decreased Subcutaneous Abscess Area in Mice
The effect of NO-np on abscess formation in Balb/c mice was
investigated (Fig. 3). Application of NO-np directly into subcuta-
neous abscesses via injection decreased the area of these structures
significantly (Fig. 3A). At day 4, the area of MRSA-infected
abscesses treated with NO-np reached ,13.24 mm
2, whereas the
area of abscesses of MRSA-infected untreated or treated with
nanoparticles only was ,17.70 mm
2 (P,0.001) and ,17.34 mm
2
(P,0.001), respectively (Fig. 3B). In separate experiments, topical
application of NO-np similarly decreased the size of the MRSA
abscesses. At day 4, the area of MRSA-infected abscesses topically
treated with NO-np was ,17.02 mm
2 whereas the area of
abscesses of MRSA-infected untreated or treated with nanoparti-
cles only was ,20.10 mm
2 and ,21.90 mm
2 (P,0.05), respec-
tively. Notably, complete abscess resolution of MRSA-infected and
NO-np-treated mice is 762 days in comparison with ,14–21 days
in the other infected groups (data not shown).
Figure 1. NO-np inhibits MRSA growth in vitro. The effect of NO in
MRSA growth kinetics after 24 h co-culture was determined using
Bioscreen C analysis. MRSA was grown in the absence or presence of
nanoparticles with NO (NO-np) or without NO (np). Each point
represents the average of four measurements and error bars denote
standard deviations.
doi:10.1371/journal.pone.0007804.g001
Figure 2. NO-np killed MRSA in subcutaneous abscesses. (A)
Abscess bacterial burden (CFU; colony forming units) in mice infected
subcutaneously with 10
7 MRSA and treated with NO-np is significantly
lower than untreated or np-treated mice (n=20 abscesses per group).
Each point represents an abscess. Dashed lines are the averages of the
results and error bars denote standard deviations. Asterisks denote
P value significance (** P,0.001) calculated by analysis of variance and
adjusted by use of the Bonferroni correction. (B) Histological analysis of
Balb/c mice untreated MRSA-infected, np-treated MRSA-infected, and
MRSA-infectedtreated withNO,day 4.Micewere infectedwith10
7 MRSA.
Representative H&E-stained sections of the skin lesions are shown with
the Insets showing Gram staining of MRSA. Scale bars: 25 mm.
doi:10.1371/journal.pone.0007804.g002
Figure 3. NO-np decreases subcutaneous abscess area in mice.
(A) Abscesses of Balb/c mice untreated MRSA-infected, np-treated
MRSA-infected, and MRSA-infected treated with NO-np, day 4. Arrows
denote abscesses. Inset shows a representative purulent abscess 4 days
after MRSA infection. Scale bar: 5 mm. (B) Abscess area analysis of Balb/
c mice subcutaneous lesions. Abscesses were infected with MRSA and
untreated or treated in the absence or presence of NO. Each point
represents an abscess. Dashed lines are the averages of the results for
fourteen measurements, and error bars denote standard deviations.
Asterisks denote P value significance (** P,0.001) calculated by analysis
of variance and adjusted by use of the Bonferroni correction.
doi:10.1371/journal.pone.0007804.g003
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Preventing MRSA Collagen Degradation
The mechanisms through which the NO-nps accelerate wound
healing were further explored by examining whether NO-nps
prevented collagen degradation by MRSA in infected tissue (Fig. 4).
Collagen content was highest in infected wounds treated with NO-
nps (Fig. 4A). The dispersed blue stain indicated thicker and more
mature tissue collagen formation in abscesses treated with NO-np,
suggesting that NO-np exposure maintained dermal architecture
through bacterial clearance, and ultimately guarding collagen.
Figure 4B is a morphometric analysis of the data shown in
Figure 4A.
NO-np Induces Cytokine Expression by the Host
We measured the cytokine response in the abscesses of mice
subcutaneously infected with MRSA. At day 4 post-infection,
abscess tissue of infected mice treated with NO-np contained
significantly higher quantities of TNF-a, IFN-c, IL-12, IL-1b,
MCP-1, and TGF-b than that of np or untreated mice (Table 1).
Also, abscess tissue of infected mice treated with NO-np exhibited
reduced levels of IL-4 and IL-10. Moreover, control and np-
treated mice did not show evidence of a consistent pattern of
cytokine expression.
NO-np Reduces Angiogenesis in MRSA Abscesses
We investigated the effect of NO-np on angiogenesis in MRSA
abscesses by measuring the expression of CD34 (Fig. 5). Tissue
sections from untreated or np-treated MRSA-infected murine
abscesses displayed dense vascularization in tissue in which high
numbers of bacteria were present (Fig. 5; insets). In contrast,
abscesses of NO-np treated MRSA-infected mice, showed minimal
formation of blood vessels in the setting of reduced bacterial
burden (Fig. 5; insets).
NO-np Attenuates Cellular Damage of RHE Tissue
Infected with MRSA
The control reconstituted human epidermal (RHE) tissue was
selected as it is representative of a normal keratinizing epithelium,
comprised of basal cells, spinous keratinocytes, granular keratino-
cytes with basophilic keratohyaline granules, and keratinizing cells,
yet without the capacity for recruitment of inflammatory cells that
may exacerbate host tissue damage (Fig. 6A). RHE infected with
MRSA and treated with NO-np exhibited less severe histological
changes than untreated tissue (Fig. 6A). Infection with MRSA
caused severe attenuation of the RHE by 24 h (‘‘atrophy’’) with
flattening of all layers of the epithelium. There were no
keratohyaline granules (Fig. 6A). The numbers of apoptotic cells
increased and there was separation between the basal cells and the
overlying spinous keratinocytes. There was severe intracellular
edema, particularly in the basal cells. In general, the basal cells and
spinous keratinocytes in the epithelium were disorganized. There
Figure 4. NO-np prevents MRSA collagen degradation in
subcutaneous abscesses. (A) Histological analysis of Balb/c mice
untreated MRSA-infected, np-treated MRSA-infected, and MRSA-infected
treated with NO-np, day 4. Mice were infected with 10
7 bacterial cells.
The blue stain indicates collagen. Scale bar: 25 mm. (B) Quantitative
measurement of collagen intensity in 20 representative fields of the
same size for untreated MRSA-infected, np-treated MRSA-infected, and
MRSA-infected treated with NO-np. Bars are the averages of the results,
and error bars denote standard deviations. Asterisks denote P value
significance (*, P,0.05 in comparing MRSA-infected np and untreated
control groups; **, P,0.001 in comparing MRSA-infected NO-np and
untreated control groups; #, P,0.01 in comparing MRSA-infected np
and NO-np groups) calculated by analysis of variance and adjusted by
use of the Bonferroni correction.
doi:10.1371/journal.pone.0007804.g004
Table 1. Cytokine levels in abscesses of mice.
Cytokine levels (pg/mL) (Average 6 SEM)
IL-12 IFN-c TNF-a IL-4 IL-10 TGF-b IL-1b MCP-1
Untr 618.7963.84 152.561.32 8560.5 56.7662.32 58.6667.86 911.7663.38 45.0661.56 36.5460.95
Np 592.5764.47 158.0762.15 83.760.31 74.1765










n=7 mice per group.
aValue significantly greater than the value for control mice (P,0.05).
bValue significantly less than the value for control mice (P,0.05).
doi:10.1371/journal.pone.0007804.t001
Figure 5. NO-np decreases vascularization in the setting of
MRSA abscesses. Histological analysis of untreated, np-treated and
NO-np treated MRSA-infected Balb/c mice, day 4. Mice were infected
with 10
7 MRSA. The brown staining indicates vascularization. Repre-
sentative CD34-immunostained sections of the skin lesions are shown
with the Insets representing Gram of MRSA. White arrows denote Gram
positive cocci. Scale bars: 25 mm.
doi:10.1371/journal.pone.0007804.g005
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the overlying spinous keratinocytes. This suprabasilar separation
could be section artifact, but this occurred reproducibly suggesting
that this phenomenon was associated with progressive superficial
infection and structural disorganization. Additionally, the tissues
show signs of bacterial penetration.
To quantify cell injury, we compared the levels of LDH released
after MRSA was co-cultured with RHE in the presence or absence
of NO nanoparticles for 24 h (Fig. 6B). Co-culture in the absence
of NO-np caused a significant change in LDH level. The LDH
results correlated with the tissue damage seen by light microscopy.
MRSA co-culture in the absence of NO-np had the highest level of
the LDH and tissue damage, whereas the tissue infected with
bacteria and treated with NO-np had significantly lower levels of
LDH and less histological damage.
Discussion
The growing danger of life-threatening infections and the rising
economic burden of resistant bacteria have created a demand for
new antibacterial therapeutics. The use of nanoparticles as
delivery vehicles for bactericidal agents represents a new paradigm
in the design of antibacterial therapeutics. Nitric oxide (NO), a
diatomic free radical that plays a key role in the natural immune
system response to infection [14], represents an alternative
approach in the design of antibacterial nanoparticles. Moreover,
we recently showed the applicability of topically applied NO
through nanoparticles (NO-np) to superficial SA skin infections
[13]. In the present study, NO-np is effective at killing pathogenic
MRSA in infected subcutaneous abscesses when applied topically
or intradermally. The avascular and biofilm-like nature of
bacterial abscesses and the colonization/infection of resistant
microbial species have undermined the efficacy of conventional
antibiotic therapy. Furthermore, the need of surgical drainage of
abscesses underscores the need for novel therapeutic approaches,
such as the sustained delivery of NO.
In our previous work, we showed that NO-np were effective
against 20 different clinical isolates of MRSA (11 strains) and
MSSA (9 strains) using CFU analysis [13]. However, to better
define the activity of the NO-np on MRSA, a real time-killing
assay was performed in tryptic soy broth (TSB) using a Bioscreen
C device. Such real time-kill studies offer valuable information
regarding the temporal efficacy of antimicrobial agents [15].
Conventional antibacterial susceptibility tests such as the mini-
mum bactericidal concentration (MBC) assays do not allow for
acute temporal studies. In TSB cultures of MRSA, NO-np
significantly reduced bacterial growth when compared with MRSA
grown with np only or medium alone. Interestingly, the highest
concentration of np without NO resulted in a significant reduction
in bacterial growth at 16 h, which is likely due to the effects of
chitosan on the np core. The antimicrobial activity of chitosan, a
hydrophilic biopolymer industrially obtained by N-deacetylation of
crustacean chitin, has been observed against a wide variety of
microorganisms including fungi, algae, and bacteria [11].
Our studies demonstrated that NO-np have significant
antimicrobial efficacy in the setting of MRSA abscesses. Bacterial
abscesses can lead to serious complications including sepsis, tissue
damage, and death. Abscesses are difficult to treat due to their
tendency to prevent immune cells from attacking or reaching the
causative microorganism. In this regard, since NO is a gas, it is
able to diffuse into the abscess thereby reducing bacterial burden
and the area of subcutaneous abscesses by inducing vascular
permeability and vasodilation. Furthermore, NO stimulates the
infiltration of immune cells such as neutrophils, macrophages, and
lymphocytes [16]. NO-np can potentially induce a protective
immune response capable of containing the infection, therefore
preventing systemic dissemination.
Another benefit of NO-np treatment of MRSA abscesses is the
stimulation of healing by induction of collagen deposition. NO
promotes wound healing through collagen secretion by fibroblasts
[17,18,19]. Acceleration of wound healing by nitric oxide donors
has been demonstrated previously [20]. Indeed, accelerated
healing of gastric ulcers has been demonstrated in rats treated
with a nitric oxide-releasing derivative of diclofenac, and a similar
effect could be observed by treating the rats with glyceryl trinitrate
[21]. Further, Thornton et al. demonstrated that collagen
deposition was enhanced in wounded rats transfected in vivo with
the gene for inducible nitric oxide synthase, and the increased
nitric production within the wound milieu preceded the observed
increase in collagen synthesis [22]. Additionally, we recently
suggested that topically applied NO-np might also prevent
collagen degradation by bacterial collagenases through a reduction
in bacterial burden [13]. Bacteria impair repair processes by
producing toxic byproducts and competing with cells for oxygen
and nutrients [23].
In treating MRSA subcutaneous abscesses with NO-np, as
proposed in our study, we showed that NO-np can modulate
immune responses to facilitate the reduction of bacterial burden.
This is the highest priority in treating chronic and non-healing
abscesses since a persistent infection and accumulation of bacterial
antigens, as commonly seen in microbial abscesses, can impair host
responses [24]. A persistent infection can further disrupt the normal
process of healing by impairing recruitment and migration of
immune cells to the site of injury, leading to abnormal levels
of cytokines and growth factors [25]. The success of the chronic
abscess elimination process by NO-np stimulation possibly depends
Figure 6. NO reduce cellular damage of reconstituted epider-
mal tissue infected with MRSA. (A) NO-np attenuate cellular
damage of reconstituted epidermal tissue infected with MRSA.
Reconstituted human epidermis control group had no bacteria or
nanoparticles, reconstituted human epidermis infected with SA, and
reconstituted human epidermis infected with SA and treated with NO-
np. Scale bar, 10 mm. (B) Relative LDH activity measured in the tissue
culture supernatant by reconstituted human epidermal tissue after 24 h
co-culture with SA in the absence or presence of NO-np. Bars are the
averages of the results for three measurements, and error bars denote
standard deviations. Asterisks denote P value significance (*, P,0.05 in
comparing the MRSA+NO-np group with the control group; **, P,0.001
in comparing the MRSA group with control group; #, P,0.01 in
comparing the MRSA group with MRSA+NO-np group) calculated by
analysis of variance and adjusted by use of the Bonferroni correction.
doi:10.1371/journal.pone.0007804.g006
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of signals that coordinate cellular processes. For instance, the
presence of high levels of pro-inflammatory IL-12 might be related
to its anti-angiogenic activity, which can block the formation of
new blood vessels, therefore, preventing bacterial dissemination to
other organs or tissues. This is accomplished by increasing
production of IFN-c, which in turn inhibits endothelial cell
motility and vascularization. In this regard, tissue sections stained
for CD34, a marker for blood vessel formation, demonstrated that
NO-np reduces angiogenesis in MRSA abscesses. In fact, the
downregulation of IL-10, which can antagonize IFN-c effects [26],
suggest that NO-np might also impede MRSA dissemination
within phagocytes. Additionally, other pro-inflammatory cyto-
kines/chemokines, particularly TNF-a,I L - 1 b, and MCP-1 were
up-regulated by NO-np. Sustained expression of these pro-
inflammatory effector molecules permits a prolonged presence of
neutrophils, macrophages, lymphocytes, and mast cells in the
chronic abscess contributing to an effective inflammatory response
and bacterial clearance [27]. Nitric oxide activates latent TGF-b,
which is believed to regulate collagen deposition by fibroblasts
[28,29]. Furthermore, elevated levels of IFN-c,T N F - a and IL1-b
have been shown to directly increase the levels TGF-b [30].
In summary, application of NO as topical agents has been used
with success in augmenting wound healing and reducing wound
bacterial burden [6,13]. The presented data show that NO-np
have both antimicrobial and wound-healing properties. Overall,
the presented results show that the topical or intradermal
application of NO-np is highly effective against subcutaneous
MRSA abscesses in a murine model. Conceivably, this technology
might be used as a potential therapy prior to or in addition to
surgical drainage of bacterial abscesses. It is further possible that
the NO-np could be useful in the treatment of deep abscesses via
injection into tissues such as the lung or liver. Interestingly, the
NO-np appear to significantly stimulate the immune system.
These results suggest that this platform has the potential to serve as
a novel, easily administered class of topical antimicrobials for the
treatment of subcutaneous infections and abscesses.
Materials and Methods
Ethics Statement
All animal studies were conducted according to the experimen-
tal practices and standards approved by the Animal Welfare and
Research Ethics Committee at the Albert Einstein College of
Medicine.
Methicillin-Resistant SA 6498
Methicillin-resistant SA (MRSA) 6498 is a clinical isolate selected
for this study because the strain is resistant to diverse commonly
used antibiotics and it was extensively utilized in our prior
superficial wound model [13]. The strain was collected from a
patient’s wounds at Montefiore Medical Center, Bronx, NY and
stored in BHI broth (BBL, Cockeysville, MD) containing 40%
glycerol at 280uC until use, and then was grown in Tryptic Soy
broth (TSB; MP Biomedicals, LLC, Solon, OH) overnight at 37uC
with rotary shaking at 150 rpm. Growth was monitored by
measuring the optical density at 600 nm (Bio-Tek, Winooski, VT).
Synthesis of NO-np
The synthesis of NO-np was recently reported along with its
potential as a treatment for superficial infections [7,13]. Briefly, a
hydrogel/glass composite was synthesized using a mixture of
tetramethylorthosilicate (TMOS), polyethylene glycol (PEG),
chitosan, glucose, and sodium nitrite in 0.5 M sodium phosphate
buffer (pH 7). The nitrite was reduced to NO within the matrix
due to the glass properties of the composite effecting redox
reactions initiated with thermally generated electrons from
glucose. After redox reaction, the ingredients were combined
and dried with a lyophilizer, resulting in a fine powder comprised
of nanoparticles containing nitric oxide. Once exposed to an
aqueous environment, the hydrogel properties of the composite
allow for opening of water channels inside the particles, facilitating
the release of the trapped NO over extended time periods. Control
nanoparticles (np) consist of the same formulation as NO-np, but
without the addition of sodium nitrate.
Susceptibility of MRSA 6498 to NO-np
To evaluate the susceptibility of MRSA to NO-np, TSB was
inoculated with a fresh colony grown on BHI plates and suspended
in 1 mL of medium. A suspension of 100 mLo fM R SA was
transferred to a 200-well plate with 100 mL of TSB per well
containing NO-np or np (1.25, 2.5, or 5 mg/mL). Bacteria and
nanoparticles were incubated at 37uC for 24 h. Wells containing
bacteria with TSB alone was used as a control. Growth was
estimated by measuring optical density at 600 nm every 30 min
using a Bioscreen C microplate reader (Growth Curves USA,
Piscataway, NJ).
In Vitro Infection Model
Reconstituted human tissues were obtained from SkinEthic
Laboratory (Nice, France) and reconstituted by incubating in
serum-free, MCDB 153 defined medium (Colonetics, San Diego,
CA, USA), containing 5 mg/mL insulin, 1.5 mM CaCl2, and
0.4 mg/mL hydrocortisone without antibiotics in 6-well tissue
culture plates (Corning Inc., Corning, NY, USA) according to the
manufacturer’s instructions. The reconstituted human epidermis
(RHE) was generated from human keratinocytes derived from
juvenile foreskin obtained during surgery. Cultures were fully
differentiated three-dimensional tissues, grown on the air-liquid
interface for 14 days prior to delivery. The tissues were inoculated
with 10
7 MRSA 6498 in 100 mL PBS by adding the cell suspension
to the 1 mL cell culture medium in the absence or presence of
5 mg/mL of NO-np. Control cultures were grown in medium
inoculated with 50 mL PBS. All cultures were incubated at 37uC
with 5% CO2 at 100% humidity for 24 h. Tissue inserts were
removed, fixed in 10% formalin for 24 h, processed, and
embedded in paraffin. Four micron vertical sections were fixed
to glass slides, stained with hematoxylin and eosin (H&E) and
examined by light microscopy.
Lactate Dehydrogenase (LDH) Measurements
The release of LDH from the HSF or RHE into the medium
was monitored as a measure of cell damage. LDH in medium from
cultures containing uninfected and infected tissues was measured
at 24 h by CytoTox-ONE
TM kit (Promega, Madison, WI)
according to the manufacturer’s instructions. MRSA 6498 cells
alone incubated under identical conditions were included as
negative controls. The LDH released in the presence of bacteria
was expressed relative to the untreated control tissue with the
LDH activity of MRSA cells alone subtracted from the LDH of the
tissue plus the bacteria.
In Vivo Abscess Model and NO-np Treatment
To investigate the antimicrobial efficacy of NO-np for
subcutaneous abscesses formed by MRSA, female Balb/c mice
(6 to 8 weeks old; National Cancer Institute, MD) were
anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine,
NO Treats S. aureus Abscesses
PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e7804the hair on their flanks was shaved, and the skin disinfected with
iodine. Then, a suspension of 100 mL with 10
7 SA 6498 in PBS was
inoculated subcutaneously in each flank of the animals (two
abscesses per mouse). The next day (day 2), a suspension with
5 mg/mL of NO-np or np dissolved in PBS was injected into or
topically applied above the abscesses. Mice receiving topical
therapy were also treated with a second topical application of NO-
np or np on day 3. Untreated, infected and non-infected mice
were used as additional controls. On day 4, the mice were
euthanized and the abscesses were excised, homogenized, and
cultured quantitatively by plating on tryptic soy agar.
Histological Processing
At day 4 after MRSA abscess formation after infection and
treatment as above, abscess tissues were excised from euthanized
mice, fixed in 10% formalin for 24 h, processed, and embedded in
paraffin. Four micron vertical sections were fixed to glass slides
and subjected to H&E, Gram, Gomori’s trichrome, or CD34
staining to observe the tissue morphology, bacteria, collagen
deposition, or vascularization, respectively. Slides were examined
by light microscopy with an Olympus AX70 (Melville, NY)
microscope, and images were obtained (QImaging Retiga 1300
digital camera [Burnaby, British Columbia, Canada]) with
QCapture Suite V2.46 software (QImaging).
Abscess Area Analysis
Abscess area analysis was performed at day 4 after infection.
Each abscess was measured using a caliper and the area was
determined.
Cytokine Determinations
Mice were euthanized at day 4 post-infection and two abscesses
per mouse were individually homogenized in 2 mL PBS in the
presence of protease inhibitors (Complete Mini; Boehringer
Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA).
The homogenates were centrifuged at 6,000 g for 10 minutes to
remove cell debris, and the supernatant was frozen at 280uC until
tested. The supernatants were assayed for IL-1b, IL-4, IL-10, IL-
12p70, MCP-1, TNF-a, TGF-b, and IFN-c using ELISA (Becton
Dickinson Biosciences Pharmingen, San Diego, California, USA;
and eBiosciences, San Diego, California, USA). The detection
limits of cytokine assays are 7.8 pg/mL for IL-4 and MCP-1,
15.6 pg/mL for IL-1b and TNF-a, 31.3 pg/mL for IL-10 and
IFN-c, 60 pg/mL for TGF-b, and 62.5 pg/mL for IL-12p70, as
stated by the manufacturer.
Statistical Analysis
All data were subjected to statistical analysis using GraphPad
Prism 5.0 (GraphPad Software, La Jolla, CA). P values were
calculated by analysis of variance and were adjusted by use of
the Bonferroni correction. P values of ,0.05 were considered
significant.
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